Seres Therapeutics, Inc. (MCRB): R&D Expense
$49.06M
Year ended 2025-12-31
$46.64M
Trailing 12 months to 2026-06-30
-23.5%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $49.06M | -24.1% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $64.60M | -45.1% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $117.60M | +7.2% | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | $109.65M | n/c | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $141.89M | +56.7% | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | $90.57M | +13.0% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $80.14M | -16.5% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $95.95M | +7.3% | 2021-03-02, From 2018-01-01 |
| 2017-12-31 | $89.45M | +9.1% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $81.99M | +115.2% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $38.09M | +255.4% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $10.72M | +123.1% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $4.80M | n/a | 2016-03-14, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $49.06M | -24.1% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $5.74M | -27.9% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $9.90M | -23.8% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $67.75M | -0.2% |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $154.22M | +110.5% |
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $9.16M | -23.1% |
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $59.99M | -6.3% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $47.39M | +25.5% |
Compare MCRB, ELTP, MNPR, PRLD side by side · Screen every company in Pharmaceutical Preparations ↗